A randomized, double-blind, placebo-controlled trial of pseudoephedrine in coryza.
1. The aim of the present study was to assess the efficacy of pseudoephedrine in coryza. 2. In a double-blind, randomized, placebo-controlled design, 48 adults with acute coryza received a single oral dose of 60 mg pseudoephedrine (Sudafed; Pfizer Consumer HealthCare Group, Caringbah, NSW, Australia) or matching placebo. Before and after dosing, nasal airway resistance (NAR), nasal volume, the minimum intranasal cross-sectional area (MCA) and the symptom of nasal congestion were measured. 3. Pseudoephedrine produced a significant decrease in NAR (P = 0.005; 95% confidence interval (CI) 0.073, 0.383). Nasal volume increased, but this did not reach significance (P = 0.07; 95% CI -0.842, 0.034). There was no change in MCA and symptoms. 4. In conclusion, pseudoephedrine has a moderate effect in decreasing objective measures of nasal congestion in coryza.
Latte
Jenny
J
Rhinometrica Cold Study Unit, Adelaide Research & Innovation, Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, South Australia, Australia.
Taverner
David
D
Slobodian
Peter
P
Shakib
Sepehr
S
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004809:Ephedrine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000627:therapeutic use*; D015508:Nasal Obstruction / Q000188:drug therapy* / Q000503:physiopathology; D015203:Reproducibility of Results; D023842:Rhinometry, Acoustic; D013997:Time Factors
D014663:Nasal Decongestants; D004809:Ephedrine